The treatment of the elderly multiple myeloma patients.

about

Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.Melphalan: old and new uses of a still master drug for multiple myeloma.

P2860

Q36897035-B1CC0D63-3011-42EB-ADE5-B802B914A8AC Q36916889-80056813-AEA3-4BD4-A060-5D9DFD37CB16

P2860

The treatment of the elderly multiple myeloma patients.

Item

http://www.wikidata.org/entity/Q36799834

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

The treatment of the elderly multiple myeloma patients.

@ast

The treatment of the elderly multiple myeloma patients.

@en

type

Item

label

The treatment of the elderly multiple myeloma patients.

@ast

The treatment of the elderly multiple myeloma patients.

@en

prefLabel

The treatment of the elderly multiple myeloma patients.

@ast

The treatment of the elderly multiple myeloma patients.

@en

P1476

The treatment of the elderly multiple myeloma patients.

@en

P2093

Cecilia Rus

http://www.w3.org/2001/XMLSchema#string

Federica Cavallo

http://www.w3.org/2001/XMLSchema#string

Maria Teresa Ambrosini

http://www.w3.org/2001/XMLSchema#string

Mario Boccadoro

http://www.w3.org/2001/XMLSchema#string

P2860

The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.

Treatment of multiple myeloma in elderly people: long-term results in 178 patients.

Antitumor activity of thalidomide in refractory multiple myeloma.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience.

P304

469-480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190601059852

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Palumbo

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17454586

http://www.w3.org/2001/XMLSchema#string

The treatment of the elderly multiple myeloma patients.

about

P2860

P2860

The treatment of the elderly multiple myeloma patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698